CORE targets lineage-dependent pathways rather than single mutations, an approach intended to reach broader patient populations than genomics-centric precision oncology.
The company launched with oncology assets licensed from Eisai and grant support from Japan's AMED, giving it a seeded pipeline and cross-border research collaborations as it advances toward the clinic.
CORE Biomedicine addresses the precision oncology market, where genomics-centric therapies leave many patients without targeted options.
Its lineage-based approach is designed to define cancer by biological identity rather than mutations alone, positioning the company alongside precision-oncology biotechs pursuing first-in-class and best-in-class therapies.
CORE Biomedicine's pipeline develops lineage-based precision oncology therapeutics that target core biological pathways defining cancer cell identity.
The programs go beyond genomic alterations to address lineage-dependent tumor biology, aiming to expand the patient populations who benefit from targeted treatment across multiple cancer types.
